ATH
Click for more information
0.00% 0.3¢ alterity therapeutics limited

Two things:1. Why wouldn't ATH re-enlist Ph2 participants...

  1. FiveCent
    1,005 Posts.
    lightbulb Created with Sketch. 209
    clock Created with Sketch.
    28/08/24
    13:19
    Post #: 75414473
    Two things:
    1. Why wouldn't ATH re-enlist Ph2 participants (amongst new participants)for Ph3? Seems logical and would provide further valuable longer term data?
    2. If we are already talking about Ph3, this is encouraging as Ph2 must just be a formality?
    A patience game IMO from here on in.

    ATH Price at posting: 0.4¢ Sentiment: Buy Disclosure: Held
    Likes Created with Sketch. 3  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

AHK New MRE update reveals significant resource uplift at Sandy Mitchell—discover the details
right-arrow Created with Sketch.
NEWS Step out drilling confirms high-grade cobalt & associated copper at Bald Hill
right-arrow Created with Sketch.
NEWS High-grade copper assays continue to impress—resource update coming soon
right-arrow Created with Sketch.
NEWS Significant increase in revenue from faster NDIS approvals and launch of new leasing programs
right-arrow Created with Sketch.
NEWS $25M secured to fuel growth, see which company is making big moves
right-arrow Created with Sketch.
NEWS High-grade drill results confirm extension at Paddy’s Lodes—reinforcing significant discovery and growth potential at Youanmi Gold Project
right-arrow Created with Sketch.
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
0.3¢ 		Change
0.000(0.00%) 		Mkt cap ! $15.96M
Open High Low Value Volume
0.3¢ 0.3¢ 0.3¢ $18 6K

Buyers (Bids)

No. Vol. Price($)
28 17696248 0.3¢
 

Sellers (Offers)

Price($) Vol. No.
0.4¢ 129653156 26
View Market Depth
Last trade - 11.56am 04/10/2024 (20 minute delay) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.